{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:58:53Z","timestamp":1790351933498,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jmmc-online.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Molecular and Cellular Cardiology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.yjmcc.2021.10.007","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T20:13:20Z","timestamp":1635452000000},"page":"118-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["NAFLD as a continuous driver in the whole spectrum of vascular disease"],"prefix":"10.1016","volume":"163","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-gang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.yjmcc.2021.10.007_bb0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2021.04.001","article-title":"Precision medicine approaches to vascular disease: JACC focus seminar 2\/5","volume":"77","author":"Miller","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0010","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4239\/wjd.v10.i2.63","article-title":"Insulin resistance is associated with subclinical vascular disease in humans","volume":"10","author":"Adeva-Andany","year":"2019","journal-title":"World J. Diabetes"},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0015","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1016\/j.jacc.2004.12.079","article-title":"Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men","volume":"45","author":"Yan","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"issue":"24","key":"10.1016\/j.yjmcc.2021.10.007_bb0020","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/eurheartj\/ehy404","article-title":"Clinical applications of machine learning in cardiovascular disease and its relevance to cardiac imaging","volume":"40","author":"Al\u2019Aref","year":"2019","journal-title":"Eur. Heart J."},{"issue":"25","key":"10.1016\/j.yjmcc.2021.10.007_bb0025","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0030","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0035","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1146\/annurev-pathmechdis-012418-013003","article-title":"Innate immune signaling in nonalcoholic fatty liver disease and cardiovascular diseases","volume":"14","author":"Cai","year":"2019","journal-title":"Annu. Rev. Pathol."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0040","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/CIRCRESAHA.121.319059","article-title":"Nonalcoholic fatty liver disease: An emerging driver of cardiac arrhythmia","volume":"128","author":"Chen","year":"2021","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0045","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/CIRCRESAHA.119.316337","article-title":"Nonalcoholic fatty liver disease pandemic fuels the upsurge in cardiovascular diseases","volume":"126","author":"Cai","year":"2020","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0050","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"16","key":"10.1016\/j.yjmcc.2021.10.007_bb0055","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.jacc.2012.06.034","volume":"60","author":"Baldassarre","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0060","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/01.ATV.0000160613.57985.18","article-title":"Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study","volume":"25","author":"Brea","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.2337\/dc06-0135","article-title":"Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease","volume":"29","author":"Targher","year":"2006","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0070","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/MEG.0000000000000429","article-title":"Nonalcoholic fatty liver disease and carotid artery atherosclerosis in children and adults: a meta-analysis","volume":"27","author":"Madan","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"10290","key":"10.1016\/j.yjmcc.2021.10.007_bb0075","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0080","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.atherosclerosis.2012.07.002","article-title":"Liver fat content is associated with increased carotid atherosclerosis in a Chinese middle-aged and elderly population: the Shanghai Changfeng study","volume":"224","author":"Li","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0085","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2012.10.040","article-title":"The effect of obesity on the association between liver fat and carotid atherosclerosis in a multi-ethnic cohort","volume":"226","author":"Dick","year":"2013","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0090","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1111\/j.1572-0241.2008.02188.x","article-title":"Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the diabetes heart study","volume":"103","author":"McKimmie","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"22","key":"10.1016\/j.yjmcc.2021.10.007_bb0095","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1001\/jama.2015.5370","article-title":"Nonalcoholic fatty liver disease: a systematic review","volume":"313","author":"Rinella","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0100","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.atherosclerosis.2015.04.009","article-title":"Nonalcoholic fatty liver disease is an independent risk factor for atherosclerosis in young adult men","volume":"240","author":"Ozturk","year":"2015","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.yjmcc.2021.10.007_bb0105","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.atherosclerosis.2015.05.002","article-title":"Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease","volume":"241","author":"Chen","year":"2015","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/j.gastro.2016.06.001","article-title":"Persistent nonalcoholic fatty liver disease increases risk for carotid atherosclerosis","volume":"151","author":"Sinn","year":"2016","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0120","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/jgh.15523","article-title":"Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population","volume":"36","author":"Pennisi","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0125","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/liv.14322","article-title":"Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score","volume":"40","author":"Xin","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2015.11.083","article-title":"Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications","volume":"77","author":"Palombo","year":"2016","journal-title":"Vasc. Pharmacol."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0135","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jacc.2019.12.039","article-title":"Trajectories of age-related arterial stiffness in Chinese men and women","volume":"75","author":"Lu","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17040460","article-title":"NAFLD and increased aortic stiffness: parallel or common physiopathological mechanisms?","volume":"17","author":"Villela-Nogueira","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0145","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1097\/HJH.0b013e32833a7de6","article-title":"Increased arterial stiffness in nonalcoholic fatty liver disease: the cardio-GOOSE study","volume":"28","author":"Salvi","year":"2010","journal-title":"J. Hypertens."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0150","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.112.252957","article-title":"Nonalcoholic fatty liver disease is associated with atherosclerosis in middle-aged and elderly Chinese","volume":"32","author":"Huang","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0155","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000341248","article-title":"The association between nonalcoholic fatty liver disease, metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensive individuals","volume":"123","author":"Kim","year":"2012","journal-title":"Cardiology"},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0160","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/heartjnl-2013-305099","article-title":"Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population","volume":"100","author":"Kim","year":"2014","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0165","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/liv.12994","article-title":"Increasing aortic stiffness is predictive of advanced liver fibrosis in patients with type 2 diabetes: the Rio-T2DM cohort study","volume":"36","author":"Leite","year":"2016","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0170","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.numecd.2014.10.002","article-title":"Non-alcoholic fatty liver disease is associated with progression of arterial stiffness","volume":"25","author":"Li","year":"2015","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0175","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41575-019-0169-z","article-title":"NAFLD in children: new genes, new diagnostic modalities and new drugs","volume":"16","author":"Nobili","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0180","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/hep.26495","article-title":"Importance of cardiometabolic risk factors in the association between nonalcoholic fatty liver disease and arterial stiffness in adolescents","volume":"58","author":"Huang","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1152\/physrev.00047.2009","article-title":"Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives","volume":"91","author":"Chiu","year":"2011","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0190","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.20781","article-title":"Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease","volume":"42","author":"Villanova","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0195","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.atherosclerosis.2012.06.005","article-title":"Nonalcoholic fatty liver disease is associated with subclinical atherosclerosis independent of obesity and metabolic syndrome in Asian Indians","volume":"223","author":"Thakur","year":"2012","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0200","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12020-012-9712-1","article-title":"Assessment of endothelial function in patients with nonalcoholic fatty liver disease","volume":"43","author":"Colak","year":"2013","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0205","doi-asserted-by":"crossref","first-page":"8825","DOI":"10.1038\/s41598-020-65835-y","article-title":"Endothelial dysfunction in nonalcoholic steatohepatitis with low cardiac disease risk","volume":"10","author":"Al-Hamoudi","year":"2020","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0210","doi-asserted-by":"crossref","first-page":"H1298","DOI":"10.1152\/ajpheart.00306.2014","article-title":"Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease","volume":"307","author":"Pugh","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0215","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/ijo.2016.123","article-title":"Exercise-induced improvements in liver fat and endothelial function are not sustained 12 months following cessation of exercise supervision in nonalcoholic fatty liver disease","volume":"40","author":"Pugh","year":"2016","journal-title":"Int. J. Obes."},{"issue":"20","key":"10.1016\/j.yjmcc.2021.10.007_bb0220","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jacc.2010.06.038","article-title":"Coronary artery calcium progression: an important clinical measurement? A review of published reports","volume":"56","author":"McEvoy","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11883-020-0820-8","article-title":"Non-alcoholic fatty liver disease and its links with inflammation and atherosclerosis","volume":"22","author":"Abdallah","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0230","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0235","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/gutjnl-2018-317666","article-title":"Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung health study","volume":"68","author":"Chang","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2008.04.045","article-title":"Markers of inflammation and coronary artery calcification: a systematic review","volume":"201","author":"Hamirani","year":"2008","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0245","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1007\/s10620-009-0935-9","article-title":"Association between nonalcoholic fatty liver disease and coronary artery calcification","volume":"55","author":"Chen","year":"2010","journal-title":"Dig. Dis. Sci."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0250","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.mayocp.2013.06.025","article-title":"Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals","volume":"88","author":"Chhabra","year":"2013","journal-title":"Mayo Clin. Proc."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0255","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2015.02.045","article-title":"Hepatic steatosis and cardiovascular disease outcomes: An analysis of the Framingham heart study","volume":"63","author":"Mellinger","year":"2015","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0260","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12872-021-02060-z","article-title":"Severe, but not mild to moderate, non-alcoholic fatty liver disease associated with increased risk of subclinical coronary atherosclerosis","volume":"21","author":"Hsiao","year":"2021","journal-title":"BMC Cardiovasc. Disord."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0265","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2337\/dc12-0515","article-title":"Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people","volume":"35","author":"Sung","year":"2012","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0270","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/hep.25593","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification","volume":"56","author":"Kim","year":"2012","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0275","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.dld.2016.09.002","article-title":"Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis","volume":"48","author":"Jaruvongvanich","year":"2016","journal-title":"Dig. Liver Dis."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0280","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/hep4.1199","article-title":"Association of hepatic steatosis with subclinical atherosclerosis: systematic review and meta-analysis","volume":"2","author":"Kapuria","year":"2018","journal-title":"Hepatol. Commun."},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202666","article-title":"Non-alcoholic fatty liver disease is a strong predictor of coronary artery calcification in metabolically healthy subjects: a cross-sectional, population-based study in middle-aged subjects","volume":"13","author":"Gummesson","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0290","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/hep.30974","article-title":"Clinical utility of an increase in magnetic resonance elastography in predicting fibrosis progression in nonalcoholic fatty liver disease","volume":"71","author":"Ajmera","year":"2020","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0295","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/apt.16324","article-title":"Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease","volume":"53","author":"Park","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0300","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.atherosclerosis.2006.04.006","article-title":"Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study","volume":"191","author":"Schindhelm","year":"2007","journal-title":"Atherosclerosis"},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0305","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1111\/j.1572-0241.2008.02034.x","article-title":"Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study","volume":"103","author":"Dunn","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0310","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.atherosclerosis.2008.12.012","article-title":"Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans","volume":"205","author":"Yun","year":"2009","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0315","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.21327","article-title":"Long-term follow-up of patients with NAFLD and elevated liver enzymes","volume":"44","author":"Ekstedt","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0320","doi-asserted-by":"crossref","first-page":"d6891","DOI":"10.1136\/bmj.d6891","article-title":"Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study","volume":"343","author":"Lazo","year":"2011","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0325","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.26156","article-title":"Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States","volume":"57","author":"Kim","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0330","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.yjmcc.2021.10.007_bb0335","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","article-title":"Nonalcoholic fatty liver disease and fibrosis associated with increased risk of cardiovascular events in a prospective study","volume":"18","author":"Baratta","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0340","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.cgh.2020.07.030","article-title":"Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease","volume":"19","author":"Meyersohn","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0345","doi-asserted-by":"crossref","first-page":"l5367","DOI":"10.1136\/bmj.l5367","article-title":"Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults","volume":"367","author":"Alexander","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0350","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2020-322786","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","author":"Simon","year":"2021","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0355","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0360","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/eurheartj\/ehx662","article-title":"Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals","volume":"39","author":"Lauridsen","year":"2018","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0365","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gutjnl-2017-313884","article-title":"Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases","volume":"66","author":"Adams","year":"2017","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0370","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/hep.23789","article-title":"Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data","volume":"52","author":"Ghouri","year":"2010","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0375","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jhep.2013.05.044","article-title":"From NAFLD in clinical practice to answers from guidelines","volume":"59","author":"Nascimbeni","year":"2013","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0380","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.2337\/diabetes.54.12.3541","article-title":"Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients","volume":"54","author":"Targher","year":"2005","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0385","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jacl.2017.04.115","article-title":"Nonalcoholic fatty liver disease in patients with acute ischemic stroke is associated with more severe stroke and worse outcome","volume":"11","author":"Abdeldyem","year":"2017","journal-title":"J. Clin. Lipidol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194153","article-title":"Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: the reasons for geographic and racial differences in stroke cohort","volume":"13","author":"Alexander","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0395","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12933-020-01025-4","article-title":"Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study","volume":"19","author":"Kim","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0400","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/STROKEAHA.120.030433","article-title":"Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events","volume":"52","author":"Xu","year":"2021","journal-title":"Stroke"},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0405","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.tem.2019.08.006","article-title":"Emerging molecular targets for treatment of nonalcoholic fatty liver disease","volume":"30","author":"Chen","year":"2019","journal-title":"Trends Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0410","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/s41574-019-0256-9","article-title":"The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state","volume":"15","author":"Hodson","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0415","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1568008033340090","article-title":"Dual roles of adiponectin\/Acrp30 in vivo as an anti-diabetic and anti-atherogenic adipokine","volume":"3","author":"Yamauchi","year":"2003","journal-title":"Curr. Drug Targets Immune Endocr. Metabol. Disord."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0420","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","article-title":"Recent insights into the pathogenesis of nonalcoholic fatty liver disease","volume":"13","author":"Arab","year":"2018","journal-title":"Annu. Rev. Pathol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0425","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"issue":"7347","key":"10.1016\/j.yjmcc.2021.10.007_bb0430","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0435","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1161\/01.RES.0000146094.59640.13","article-title":"Antiinflammatory properties of HDL","volume":"95","author":"Barter","year":"2004","journal-title":"Circ. Res."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0440","doi-asserted-by":"crossref","DOI":"10.1038\/s41575-021-00502-9","article-title":"Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests","author":"Masoodi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0445","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/hep.31808","article-title":"Steatotic hepatocytes release mature VLDL through methionine and tyrosine metabolism in a Keap1-Nrf2-dependent manner","volume":"74","author":"Sano","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0450","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s12272-019-01178-1","article-title":"Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease","volume":"42","author":"Lee","year":"2019","journal-title":"Arch. Pharm. Res."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0455","article-title":"A conventional immune regulator MAVS blocks hepatic steatosis via maintaining mitochondrial homeostasis","author":"Fu","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0460","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.RES.0000232319.02303.8c","article-title":"Novel effect of oxidized low-density lipoprotein: cellular ATP depletion via downregulation of glyceraldehyde-3-phosphate dehydrogenase","volume":"99","author":"Sukhanov","year":"2006","journal-title":"Circ. Res."},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0465","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1182\/blood-2002-09-2711","article-title":"Oxidized low-density lipoprotein (oxLDL) triggers hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation via redox-dependent mechanisms","volume":"101","author":"Shatrov","year":"2003","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0470","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","article-title":"Immunity and inflammation in atherosclerosis","volume":"124","author":"Wolf","year":"2019","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0475","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.cmet.2020.04.011","article-title":"Low-Dose Sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis","volume":"31","author":"Jian","year":"2020","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0480","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCRESAHA.118.312563","article-title":"Mechanisms of dysfunction in the aging vasculature and role in age-related disease","volume":"123","author":"Donato","year":"2018","journal-title":"Circ. Res."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0485","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/hep.30506","article-title":"The role of innate immune cells in nonalcoholic steatohepatitis","volume":"70","author":"Cai","year":"2019","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.yjmcc.2021.10.007_bb0490","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.tem.2018.08.003","article-title":"Role of innate immune signaling in non-alcoholic fatty liver disease","volume":"29","author":"Cai","year":"2018","journal-title":"Trends Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0495","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jhep.2016.03.006","article-title":"Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis","volume":"65","author":"Gao","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0500","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hep.30822","article-title":"Hepatocyte TNF receptor-associated factor 6 aggravates hepatic inflammation and fibrosis by promoting lysine 6-linked polyubiquitination of apoptosis signal-regulating kinase 1","volume":"71","author":"Wang","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0505","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1038\/ncomms11267","article-title":"The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling","volume":"7","author":"Ji","year":"2016","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0510","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm.4453","article-title":"The deubiquitinating enzyme TNFAIP3 mediates inactivation of hepatic ASK1 and ameliorates nonalcoholic steatohepatitis","volume":"24","author":"Zhang","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0515","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.cmet.2020.03.007","article-title":"TNFAIP3 interacting protein 3 overexpression suppresses nonalcoholic steatohepatitis by blocking TAK1 activation","volume":"31","author":"Liu","year":"2020","journal-title":"Cell Metab."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0520","doi-asserted-by":"crossref","first-page":"110008","DOI":"10.1016\/j.cellsig.2021.110008","article-title":"Beclin-1 overexpression regulates NLRP3 activation by promoting TNFAIP3 in microvascular injury following myocardial reperfusion","volume":"84","author":"Sun","year":"2021","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0525","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00395-014-0434-9","article-title":"Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia\/reperfusion injury","volume":"109","author":"Zhang","year":"2014","journal-title":"Basic Res. Cardiol."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0530","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/hep.30559","article-title":"Hepatic interferon regulatory factor 6 alleviates liver steatosis and metabolic disorder by transcriptionally suppressing peroxisome proliferator-activated receptor gamma in mice","volume":"69","author":"Tong","year":"2019","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0535","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1161\/CIRCULATIONAHA.120.046464","article-title":"Hyperglycemia induces trained immunity in macrophages and their precursors and promotes atherosclerosis","volume":"144","author":"Edgar","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0540","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cmet.2019.05.014","article-title":"Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia","volume":"30","author":"Bekkering","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0545","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2018.08.012","article-title":"Interactions between dyslipidemia and the immune system and their relevance as putative therapeutic targets in atherosclerosis","volume":"193","author":"Lacy","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0550","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jhep.2016.02.002","article-title":"Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis","volume":"64","author":"Xiang","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0555","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/hep.28971","article-title":"The E3 ligase tripartite motif 8 targets TAK1 to promote insulin resistance and steatohepatitis","volume":"65","author":"Yan","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0560","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.31242","article-title":"Hepatic regulator of G protein signaling 5 ameliorates nonalcoholic fatty liver disease by suppressing transforming growth factor beta-activated kinase 1-c-Jun-N-terminal kinase\/p38 signaling","volume":"73","author":"Wang","year":"2021","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0565","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/hep.29257","article-title":"The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance","volume":"66","author":"Zhang","year":"2017","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0570","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jhep.2016.03.008","article-title":"DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity","volume":"65","author":"Xie","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0575","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hep.31277","article-title":"Milk fat globule-epidermal growth factor-factor 8 improves hepatic steatosis and inflammation","volume":"73","author":"Zhang","year":"2021","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0580","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1161\/CIRCRESAHA.109.200741","article-title":"ASK1 regulates cardiomyocyte death but not hypertrophy in transgenic mice","volume":"105","author":"Liu","year":"2009","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0585","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/cvr\/cvu004","article-title":"Dickkopf-3 attenuates pressure overload-induced cardiac remodelling","volume":"102","author":"Zhang","year":"2014","journal-title":"Cardiovasc. Res."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0590","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.002360","article-title":"Inhibition of apoptosis signal-regulating kinase 1 reduces myocardial ischemia-reperfusion injury in the mouse","volume":"1","author":"Toldo","year":"2012","journal-title":"J. Am. Heart Assoc."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0595","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00395-015-0481-x","article-title":"Dickkopf-3 protects against cardiac dysfunction and ventricular remodelling following myocardial infarction","volume":"110","author":"Bao","year":"2015","journal-title":"Basic Res. Cardiol."},{"issue":"10","key":"10.1016\/j.yjmcc.2021.10.007_bb0600","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.tips.2012.06.007","article-title":"Targeting of TAK1 in inflammatory disorders and cancer","volume":"33","author":"Sakurai","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0605","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cmet.2021.05.019","article-title":"Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1","volume":"33","author":"Wang","year":"2021","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0610","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1002\/hep.29375","article-title":"USP18 protects against hepatic steatosis and insulin resistance through its deubiquitinating activity","volume":"66","author":"An","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0615","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm.4461","article-title":"The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis","volume":"24","author":"Ji","year":"2018","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0620","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep.29616","article-title":"Hepatocyte DUSP14 maintains metabolic homeostasis and suppresses inflammation in the liver","volume":"67","author":"Wang","year":"2018","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0625","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014920","article-title":"CARD3 promotes cerebral ischemia-reperfusion injury via activation of TAK1","volume":"9","author":"Wu","year":"2020","journal-title":"J. Am. Heart Assoc."},{"issue":"12","key":"10.1016\/j.yjmcc.2021.10.007_bb0630","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1111\/jcmm.15340","article-title":"Inhibition of TGFbeta-activated protein kinase 1 ameliorates myocardial ischaemia\/reperfusion injury via endoplasmic reticulum stress suppression","volume":"24","author":"Zeng","year":"2020","journal-title":"J. Cell. Mol. Med."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101671","article-title":"Roles of the kinase TAK1 in CD40-mediated effects on vascular oxidative stress and neointima formation after vascular injury","volume":"9","author":"Song","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.yjmcc.2021.10.007_bb0640","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023239","article-title":"CD40 is essential in the upregulation of TRAF proteins and NF-kappaB-dependent proinflammatory gene expression after arterial injury","volume":"6","author":"Song","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0645","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/HYPERTENSIONAHA.115.05430","article-title":"Neuron-specific tumor necrosis factor receptor-associated factor 3 is a central regulator of neuronal death in acute ischemic stroke","volume":"66","author":"Gong","year":"2015","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0650","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12865-017-0215-y","article-title":"The imbalance of Th17\/Treg cells is involved in the progression of nonalcoholic fatty liver disease in mice","volume":"18","author":"He","year":"2017","journal-title":"BMC Immunol."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0655","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yjmcc.2019.05.009","article-title":"Disruption of the CCL1-CCR8 axis inhibits vascular Treg recruitment and function and promotes atherosclerosis in mice","volume":"132","author":"Vila-Caballer","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0660","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/1751-2980.12362","article-title":"Role of intrahepatic B cells in non-alcoholic fatty liver disease by secreting pro-inflammatory cytokines and regulating intrahepatic T cells","volume":"17","author":"Zhang","year":"2016","journal-title":"J. Dig. Dis."},{"issue":"9","key":"10.1016\/j.yjmcc.2021.10.007_bb0665","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/eurheartj\/ehaa995","article-title":"Alarmin-activated B cells accelerate murine atherosclerosis after myocardial infarction via plasma cell-immunoglobulin-dependent mechanisms","volume":"42","author":"Kyaw","year":"2021","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0670","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1161\/ATVBAHA.117.310678","article-title":"Follicular B cells promote atherosclerosis via T cell-mediated differentiation into plasma cells and secreting pathogenic immunoglobulin G","volume":"38","author":"Tay","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0675","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13148-015-0056-6","article-title":"Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease","volume":"7","author":"Zeybel","year":"2015","journal-title":"Clin. Epigenetics"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0680","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.cmet.2013.07.004","article-title":"DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery","volume":"18","author":"Ahrens","year":"2013","journal-title":"Cell Metab."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0685","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/gutjnl-2016-311526","article-title":"Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease","volume":"66","author":"Hardy","year":"2017","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0690","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13148-021-01078-6","article-title":"DNA methylation biomarkers of myocardial infarction and cardiovascular disease","volume":"13","author":"Fernandez-Sanles","year":"2021","journal-title":"Clin. Epigenetics"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0695","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1161\/CIRCRESAHA.117.312086","article-title":"Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease","volume":"122","author":"van der Harst","year":"2018","journal-title":"Circ. Res."},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0700","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrg3863","article-title":"RNA-mediated epigenetic regulation of gene expression","volume":"16","author":"Holoch","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0705","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.biocel.2014.04.002","article-title":"Regulation of microRNAs and their role in liver development, regeneration and disease","volume":"54","author":"Finch","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0710","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1053\/j.gastro.2020.05.056","article-title":"Agonist of RORA attenuates nonalcoholic fatty liver progression in mice via Up-regulation of MicroRNA 122","volume":"159","author":"Chai","year":"2020","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.yjmcc.2021.10.007_bb0715","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17101620","article-title":"miR33a\/miR33b* and miR122 as possible contributors to hepatic lipid metabolism in obese women with nonalcoholic fatty liver disease","volume":"17","author":"Auguet","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18041483","article-title":"Mir-1, miR-122, miR-132, and miR-133 are related to subclinical aortic atherosclerosis associated with metabolic syndrome","volume":"18","author":"Satrauskiene","year":"2021","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"6","key":"10.1016\/j.yjmcc.2021.10.007_bb0725","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2018.08.008","article-title":"miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis","volume":"69","author":"Liu","year":"2018","journal-title":"J. Hepatol."},{"issue":"13","key":"10.1016\/j.yjmcc.2021.10.007_bb0730","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1161\/CIRCULATIONAHA.120.051614","article-title":"MicroRNA-21 controls circadian regulation of apoptosis in atherosclerotic lesions","volume":"144","author":"Schober","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0735","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41556-018-0250-9","article-title":"Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication","volume":"21","author":"Mathieu","year":"2019","journal-title":"Nat. Cell Biol."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0740","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1172\/JCI87316","article-title":"Extracellular vesicles: masters of intercellular communication and potential clinical interventions","volume":"126","author":"Pitt","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.04.054","article-title":"SnapShot: extracellular vesicles","volume":"182","author":"Cocozza","year":"2020","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0750","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/genes4020152","article-title":"Signaling pathways in exosomes biogenesis, secretion and fate","volume":"4","author":"Urbanelli","year":"2013","journal-title":"Genes (Basel)"},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/cells9040817","article-title":"Extracellular vesicles in NAFLD\/ALD: from pathobiology to therapy","volume":"9","author":"Hernandez","year":"2020","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0760","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jhep.2019.09.014","article-title":"Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1","volume":"72","author":"Jiang","year":"2020","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0765","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1017\/S0007114515001117","article-title":"Long-term high fat feeding of rats results in increased numbers of circulating microvesicles with pro-inflammatory effects on endothelial cells","volume":"113","author":"Heinrich","year":"2015","journal-title":"Br. J. Nutr."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0770","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s12015-019-09944-w","article-title":"Delivery of LNA-antimiR-142-3p by mesenchymal stem cells-derived exosomes to breast cancer stem cells reduces tumorigenicity","volume":"16","author":"Naseri","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0775","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejpb.2020.07.026","article-title":"Exosomes as drug delivery systems: a brief overview and progress update","volume":"154","author":"Patil","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.yjmcc.2021.10.007_bb0780","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.apsb.2016.02.001","article-title":"Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges","volume":"6","author":"Ha","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0785","doi-asserted-by":"crossref","first-page":"32002","DOI":"10.1038\/srep32002","article-title":"Altered Fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease","volume":"6","author":"Wang","year":"2016","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.yjmcc.2021.10.007_bb0790","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1161\/CIRCULATIONAHA.105.579979","article-title":"Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease","volume":"113","author":"Ott","year":"2006","journal-title":"Circulation"},{"issue":"7341","key":"10.1016\/j.yjmcc.2021.10.007_bb0795","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.yjmcc.2021.10.007_bb0800","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1111\/liv.14963","article-title":"Circulating trimethylamine-N-oxide is associated with all-cause mortality in subjects with nonalcoholic fatty liver disease","volume":"41","author":"Flores-Guerrero","year":"2021","journal-title":"Liver Int."},{"issue":"17","key":"10.1016\/j.yjmcc.2021.10.007_bb0805","doi-asserted-by":"crossref","DOI":"10.1002\/mnfr.201900257","article-title":"Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease","volume":"63","author":"Tan","year":"2019","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0810","article-title":"Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis","author":"Witkowski","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0815","first-page":"814","article-title":"Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors","volume":"38","author":"Li","year":"2017","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.yjmcc.2021.10.007_bb0820","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/s41587-020-0549-5","article-title":"Directed remodeling of the mouse gut microbiome inhibits the development of atherosclerosis","volume":"38","author":"Chen","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"7818","key":"10.1016\/j.yjmcc.2021.10.007_bb0825","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41586-020-2527-y","article-title":"A leptin-BDNF pathway regulating sympathetic innervation of adipose tissue","volume":"583","author":"Wang","year":"2020","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0830","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.2337\/db11-1142","article-title":"Hypothalamic neuropeptide Y (NPY) controls hepatic VLDL-triglyceride secretion in rats via the sympathetic nervous system","volume":"61","author":"Bruinstroop","year":"2012","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0835","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmet.2015.01.004","article-title":"Central nervous system neuropeptide Y regulates mediators of hepatic phospholipid remodeling and very low-density lipoprotein triglyceride secretion via sympathetic innervation","volume":"4","author":"Rojas","year":"2015","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0840","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/01.CIR.0000079172.43229.CD","article-title":"Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction","volume":"108","author":"Sauer","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.yjmcc.2021.10.007_bb0845","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1530\/JME-17-0062","article-title":"IGF1 potentiates the pro-inflammatory response in human peripheral blood mononuclear cells via MAPK","volume":"59","author":"Wolters","year":"2017","journal-title":"J. Mol. Endocrinol."},{"issue":"5","key":"10.1016\/j.yjmcc.2021.10.007_bb0850","doi-asserted-by":"crossref","DOI":"10.1210\/endocr\/bqab040","article-title":"Hepatic Igf1-deficiency protects against atherosclerosis in female mice","volume":"162","author":"Sivasubramaniyam","year":"2021","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.yjmcc.2021.10.007_bb0855","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1113\/JP278895","article-title":"Liver sympathetic nerve activity and steatosis","volume":"598","author":"Edinburgh","year":"2020","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.yjmcc.2021.10.007_bb0860","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.048922","article-title":"Modulation of serotonin in the gut-liver neural axis ameliorates the fatty and fibrotic changes in non-alcoholic fatty liver","volume":"14","author":"Ko","year":"2021","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.yjmcc.2021.10.007_bb0865","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev.med.60.042307.110802","article-title":"The expanded biology of serotonin","volume":"60","author":"Berger","year":"2009","journal-title":"Annu. Rev. Med."},{"issue":"19","key":"10.1016\/j.yjmcc.2021.10.007_bb0870","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009179","article-title":"Regulator of G protein signaling 6 facilities cardiac hypertrophy by activating apoptosis signal-regulating kinase 1-P38\/c-JUN N-terminal kinase 1\/2 signaling","volume":"7","author":"Huang","year":"2018","journal-title":"J. Am. Heart Assoc."}],"container-title":["Journal of Molecular and Cellular Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282821002066?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022282821002066?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T20:36:12Z","timestamp":1758314172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022282821002066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":174,"alternative-id":["S0022282821002066"],"URL":"https:\/\/doi.org\/10.1016\/j.yjmcc.2021.10.007","relation":{},"ISSN":["0022-2828"],"issn-type":[{"value":"0022-2828","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NAFLD as a continuous driver in the whole spectrum of vascular disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Molecular and Cellular Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yjmcc.2021.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}